Cover Image
市場調查報告書

疫苗委託生產市場預測:主要國家、技術、企業分析

Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies

出版商 Visiongain Ltd 商品編碼 347364
出版日期 內容資訊 英文 148 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗委託生產市場預測:主要國家、技術、企業分析 Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies
出版日期: 2015年12月17日 內容資訊: 英文 148 Pages
簡介

疫苗委託生產市場總體營收預估將於2019年達到10億4730萬美元規模,預計至2026年也將呈現穩健成長。治療疫苗需求增加、以及人口老化等因素,帶動預測期內的市場成長,另外也預期將推動疫苗委託生產業務。

本報告調查全球疫苗委託生產市場,彙整了疫苗發展歷史、運作、種類及概要、目前生產技術、疫苗生產市場規模推移與預測、疫苗委託生產市場規模推移與預測、主要國家委託生產市場規模推移與預測、主要疫苗委託生產機構簡介及其努力等。

第1章 報告概要

第2章 疫苗簡介

  • 疫苗歷史
  • 疫苗運作
    • 人工免疫
  • 疫苗種類
    • 活性減毒疫苗 (LAV)
    • 重組活疫苗
    • 不活化疫苗
    • 類毒素疫苗
    • 次單位疫苗
    • 結合型疫苗
    • 重組次單位疫苗
    • DNA疫苗
    • 重組載體疫苗
    • 治療疫苗
  • 疫苗疾病預防
  • 疫苗市場成長
  • 技術、法規面改善

第3章 目前疫苗生產技術

  • 摘要:疫苗技術趨勢
  • 疫苗生產新基質
    • 移轉至細胞培養製造技術
    • 細胞培養製造的優點
    • 哺乳類細胞株
    • 鳥類細胞株
    • 植物疫苗
    • 昆蟲卵生產系統
  • 次世代表現系統&載體:產量增加
    • AdVac Technology:Crucell
    • AdCEV Vectors:AfriVax
    • Pfenex Expression Technology:Pfenex
  • 設備趨勢
    • 轉移至拋棄式單次利用設備
    • 生物反應器與疫苗生產
  • 預充填式注射劑與疫苗
    • 預充填式注射劑市場成長
    • 充填式疫苗產品
    • 充填式疫苗:成長推動因子、阻礙因子
    • 產品穩定性、品質保證計畫
  • 冷凍乾燥與疫苗製造
  • 透過細胞培養基改善產量

第4章 全球疫苗生產市場預測

  • 全球疫苗生產市場預測:概要
  • 全球疫苗市場預測
  • 全球疫苗市場:按次市場
  • 疫苗市場成長與高效率疫苗生產
  • 兒童疫苗市場概要
  • 成人預防疫苗市場概要
  • 流感疫苗市場概要
  • 治療疫苗市場概要

第5章 全球疫苗委託生產預測

  • 製藥及生物科技產業的委外
    • 委外理由
    • 委外優點
    • 疫苗生產委外的課題
    • 企業委外進行疫苗生產的理由
    • 策略委外 vs 委外戰術
  • 藥品委託生產機構 (CMO)
    • CMO提供的生產服務
    • 經常委外的疫苗生產活動
  • 藥品委託生產市場:整體收益預估
  • 疫苗委託生產市場預測
    • 市場規模實績
    • 市場預測

第6章 主要國家疫苗委託生產預測

  • 主要國家疫苗委託生產
  • 主要國家疫苗委託生產推移
  • 主要國家疫苗委託生產預測
    • 美國
    • EU5國
      • 德國
      • 義大利
      • 英國
      • 法國
      • 西班牙
    • 日本
    • 中國
    • 印度
    • 俄國
    • 巴西

第7章 主要疫苗委託生產企業預測

  • 主要疫苗委託生產機構
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • SynCo Bio Partners

第8章 疫苗生產市場:全球趨勢預測

  • 疫苗委託生產產業趨勢
  • SWOT分析

第9章 結論

  • 概要
  • 法規與品質標準構成高參與阻礙
  • 新興市場:預估呈現強勁成長

第10章 詞彙表

圖表

目錄
Product Code: PHA0083

What can be expected from the vaccine contract manufacturing market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 148-page report provides 76 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analysis and commercial developments.

See revenue forecasts for the leading international markets

How will leading national markets perform to 2026? Our study forecasts revenues in national markets including products, including:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • Brazil
  • Russia
  • India

Leading companies and potential for market growth

Overall revenue for the vaccine contract manufacturing market will reach $1047.3m in 2019, our work forecasts. We predict good revenue growth through to 2026. Increasing demands for therapeutic vaccines and an ageing population will help drive the market for vaccines over the forecast period, which in turn helps drive the vaccine contract manufacturing business.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:

  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika
  • Lonza
  • Meridian Life Science
  • Sigma Aldrich Fine Chemical (Merck)
  • Synco Bio Partners

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Vaccine contract manufacturing industry?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:

  • The emergence of developing markets as manufacturing centres
  • Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Vaccine Contract Manufacturing Market 2016-2026 report helps you

In summary, our 148-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the vaccine contract manufacturing market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for the leading national markets - US, Japan, EU5 (Germany, UK, France, Italy and Spain), China, India, Brazil and Russia
  • Assessment of leading companies - analysis of vaccine manufacturing capabilities, revenue and news (Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemical (Merck), Synco Bio Partners)
  • Discussion of what stimulates and restrains companies and the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the vaccine contract manufacturing market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government

Table of Contents

1. Report Overview

  • 1.1. World Vaccine Contract Manufacturing Market Highlights
  • 1.2. Why You Should Read This Report?
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain
  • 1.10. Exchange Rates

2. Introduction to Vaccines

  • 2.1. The History of Vaccines
  • 2.2. How Do Vaccines Work?
    • 2.2.1. Artificial Immunity
  • 2.3. Types of Vaccine
    • 2.3.1. Live, Attenuated Vaccines (LAVs)
    • 2.3.2. Recombinant Live Vaccines
    • 2.3.3. Inactivated Vaccines
    • 2.3.4. Toxoid Vaccines
    • 2.3.5. Subunit Vaccines
    • 2.3.6. Conjugate Vaccines
    • 2.3.7. Recombinant Subunit Vaccines
    • 2.3.8. DNA Vaccines
    • 2.3.9. Recombinant Vector Vaccines
    • 2.3.10. Therapeutic Vaccines
  • 2.4. Diseases Preventable with Vaccines
  • 2.5. The Rise of the Vaccines Market
  • 2.6. Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2015

  • 3.1. Summary of Vaccine Technology Trends
  • 3.2. New Substrates for Vaccine Production
    • 3.2.1. Shift towards Cell-Based Manufacturing Technology
    • 3.2.2. Benefits of Cell-Based Techniques
    • 3.2.3. Mammalian Cell Lines
      • 3.2.3.1. MCDK (Madin Darby Canine Kidney Cells)
      • 3.2.3.2. Vero Cells
      • 3.2.3.3. PerC6 Cells
    • 3.2.4. Avian-Derived Cell Lines
      • 3.2.4.1. EB66 Stem Cell Technology: Vivalis
    • 3.2.5. Plant-Based Vaccines
      • 3.2.5.1. Medicago's Proficia VLP Vaccine Technology
    • 3.2.6. Insect Egg-Based Production Systems
      • 3.2.6.1. Novavax
      • 3.2.6.2. Protein Sciences Corporation (PSC)
  • 3.3. Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1. AdVac Technology: Crucell
    • 3.3.2. AdCEV Vectors: AfriVax
    • 3.3.3. Pfenex Expression Technology: Pfenex
  • 3.4. Equipment Trends
    • 3.4.1. The Shift Towards Disposable Single-use Equipment
    • 3.4.2. Bioreactors and Vaccine Production
      • 3.4.2.1. Single-Use Bioreactors
      • 3.4.2.2. Main Applications of Disposable Bioreactors
      • 3.4.2.3. Current Single-Use Bioreactor Systems on the Market
  • 3.5. Prefilled Syringes and Vaccines
    • 3.5.1. Growing Market for Pre-Filled Syringes
    • 3.5.2. Pre-Filled Vaccine Products 2015
    • 3.5.3. Drivers and Restraints for Pre-Filled Syringes
    • 3.5.4. Product Stability and Quality Assurance Programme
      • 3.5.4.1. Paediatric H1N1 Vaccine
      • 3.5.4.2. Reported Challenges Flu Vaccines
      • 3.5.4.3. Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4. Baxter Flu Vaccine and Side Effects
      • 3.5.4.5. Reported Shelf Life With H1N1 Vaccine
  • 3.6. Lyophilisation and Vaccine Manufacturing
    • 3.6.1. Lyophilisation of Vaccines will Increase
  • 3.7. Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2016-2026

  • 4.1. Overview of the Global Vaccine Manufacturing Market 2016-2026
  • 4.2. World Vaccine Market Forecast 2016-2026
  • 4.3. The Global Vaccine Market By Submarket, 2014 and 2015
  • 4.4. Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
  • 4.5. Paediatric Vaccines Market Overview
  • 4.6. Adult Prophylactic Vaccines Market Overview
  • 4.7. Influenza Vaccines Market Overview
  • 4.8. Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2016-2026

  • 5.1. Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 5.1.1. Reasons to Outsource
    • 5.1.2. Benefits of Outsourcing
    • 5.1.3. The Challenges in Outsourcing Vaccine Manufacturing
    • 5.1.4. Why Should Companies Outsource Vaccine Manufacturing?
    • 5.1.5. Strategic Outsourcing vs. Tactical Outsourcing
    • 5.1.6. Virtual Companies
  • 5.2. Contract Manufacturing Organisations (CMOs)
    • 5.2.1. Manufacturing Services Offered by CMOs
    • 5.2.2. Vaccine Manufacturing Activities Typically Outsourced
  • 5.3. The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2026
  • 5.4. Contract Manufacturing Market for Vaccines 2016-2026
    • 5.4.1. Market Size for Contract Manufacturing of Vaccines 2014
    • 5.4.2. Vaccine Contract Manufacturing Market Forecast 2016-2026

6. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026

  • 6.1. The Leading National Markets for Vaccine Contract Manufacturing
  • 6.2. The Leading National Markets for Vaccine Contract Manufacturing, 2014-2016
  • 6.3. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026
    • 6.3.1. The US Vaccine Contract Manufacturing Market Forecast, 2016-2026
    • 6.3.2. The EU5 Vaccine Contract Manufacturing Market, 2014 and 2015
      • 6.3.2.1. The EU5 Vaccine Contract Manufacturing Market, 2016-2026
      • 6.3.2.2. The German Vaccine Contract Manufacturing Market, 2016-2026
      • 6.3.2.3. The Italian Vaccine Contract Manufacturing Market, 2016-2026
      • 6.3.2.4. The UK Vaccine Contract Manufacturing Market, 2016-2026
      • 6.3.2.5. The French Vaccine Contract Manufacturing Market, 2016-2026
      • 6.3.2.6. The Spanish Vaccine Contract Manufacturing Market, 2016-2026
    • 6.3.3. The Japanese Vaccine Contract Manufacturing Market, 2016-2026
    • 6.3.4. The Chinese Vaccine Contract Manufacturing Market, 2016-2026
    • 6.3.4. The Indian Vaccine Contract Manufacturing Market, 2016-2026
    • 6.3.5. The Russian Vaccine Contract Manufacturing Market, 2016-2026
    • 6.3.6. The Brazilian Vaccine Contract Manufacturing Market, 2016-2026

7. Leading Vaccine Contract Manufacturing Companies, 2016-2026

  • 7.1. Leading Vaccine Contract Manufacturing Organisations
  • 7.2. Baxter BioPharma Solutions
  • 7.3. Boehringer Ingelheim
    • 7.3.1. Recent Financial Performance
    • 7.3.2. Ben Venue Laboratories
    • 7.3.3. Manufacturing Deals 2011-2015
  • 7.4. Catalent
    • 7.4.1. Recent Financial Performance
    • 7.4.2. Catalent: Financial Performance by Segment, 2011-2015
    • 7.4.3. Catalent Injectable Vaccines
    • 7.4.4. Catalent: Zydis Technology
    • 7.4.5. Regional Market Expansion Strategy
  • 7.5. Charles River Laboratories
    • 7.5.1. Recent Financial Performance, 2011-2014
    • 7.5.2. Financial Performance by Segment, 2010-2015
    • 7.5.3. Recent Financial Performance, 2015
    • 7.5.4. Vaccine Manufacturing Services
    • 7.5.5. Charles River Avian Vaccine Services
    • 7.5.6. Vaccine Manufacturing Expansion
    • 7.5.7. Outlook and Early Stage Restructuring
    • 7.5.8. Partnerships
      • 7.5.8.1. Partnership with AstraZeneca
      • 7.5.8.2. Partnership with Batavia
  • 7.6. IDT Biologika GmbH
  • 7.7. Lonza
    • 7.7.1. Recent Financial Performance
    • 7.7.2. Financial Performance in H1 2015
    • 7.7.3. Manufacturing Division Restructuring
  • 7.8. Meridian Life Science
    • 7.8.1. Recent Financial Performance, 2010-2014
    • 7.8.2. Recent Financial Performance by Segment, 2011-2014
    • 7.8.3. Current Developments, 2015
  • 7.9. Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • 7.10. SynCo Bio Partners
    • 7.11.1. Recent Developments
      • 7.11.1.1. Expansion of Facilities
      • 7.11.1.2. FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2016-2026

  • 8.1. Vaccine Contract Manufacturing Industry Trends
  • 8.2. Strengths
    • 8.2.1. Many Companies Cannot Afford In-house Capabilities
    • 8.2.2. Outsourcing Improves Time to Market
    • 8.2.3. Manufacturers Get Access to Specialised Technologies
    • 8.2.4. Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 8.3. Weaknesses
    • 8.3.1. Mass Vaccine Manufacturing Kept In-house
    • 8.3.2. A Highly Fragmented Vaccine Contract Manufacturing Market
    • 8.3.3. An Unpredictable Supply and Demand Business Model
  • 8.4. Opportunities
    • 8.4.1. Many Vaccines in the Product Pipeline
    • 8.4.2. Emerging Market's Growing Demand for Vaccines
      • 8.4.2.1. Dynamic Change: Emerging Markets are Major Vaccine Developers
    • 8.4.3. Changing World Demographics
  • 8.5. Threats
    • 8.5.1. Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
    • 8.5.2. The Public are Slow to Accept Novel Technologies
    • 8.5.3. Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion

  • 9.1. Overview
  • 9.2. Regulatory and Quality Standards Create High Barriers of Entry
  • 9.3. Emerging Markets Will Show Stronger Growth

10. Glossary

List of Tables

  • Table 1.1: Currency Exchange Rates, 2014
  • Table 2.1: Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1: Vaccine Development Pipeline Using Crucell's AdVac Technology, 2015
  • Table 3.2: Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2015
  • Table 3.3: Companies Providing Disposable Biomanufacturing Platforms/Systems, 2015
  • Table 3.4: Some Leading Pre-Filled Syringe Vaccine Products, 2015
  • Table 3.5: Prominent Lyophilised Vaccines, 2015
  • Table 3.6: Examples of Serum-Free Media for Vaccine Manufacturing, 2015
  • Table 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2026
  • Table 4.2: The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2014-2015
  • Table 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.1: The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2014-2015
  • Table 6.2: The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.3: The Leading National Vaccine Contract Manufacturing Markets Forecast: Market Shares (%), 2016 and 2026
  • Table 6.4: The US Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.5: The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m) and Market Share (%) by Country, 2014-2015
  • Table 6.6: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.7: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.8: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.9: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.10: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.11: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.12: The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.13: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.14: The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.15: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 6.16: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 7.1: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2014
  • Table 7.2: Catalent: Revenue($m) and AGR (%), 2010-2015
  • Table 7.3: Catalent by Segment: Revenue($m), AGR (%), and Intersegment Revenue Eliminations, 2011-2015
  • Table 7.4: Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2014
  • Table 7.5: Charles River Laboratories: Newly Revised Reportable Segments
  • Table 7.6: Charles River Laboratories: Revenue ($bn) by Segment, 2010-2012
  • Table 7.7: Charles River Laboratories: Revenue ($bn) by Segment, 2013-2014
  • Table 7.8: Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2015
  • Table 7.9: Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2015
  • Table 7.10: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2014
  • Table 7.11: Meridian Bioscience: Revenue ($m), AGR (%), 2010-2014
  • Table 7.12: Meridian Bioscience: Revenue ($m) and AGR (%) by Segment, 2011-2014
  • Table 7.13: SynCo Bio Partners Capabilities 2015
  • Table 8.1: SWOT Analysis of the Vaccine Contract Manufacturing Market, 2016-2026

List of Figures

  • Figure 3.1: Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2015
  • Figure 3.2: Medicago's Product Pipeline, 2015
  • Figure 3.3: Novavax' Insect Egg-Based Vaccine Production Process, 2015
  • Figure 3.4: Pre-filled Syringes Market: Drivers and Restraints, 2015-2026
  • Figure 4.1: The Global Vaccine Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.2: The Global Vaccine Market: Market Share by Submarket (%), 2015
  • Figure 5.1: Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2015
  • Figure 5.2: The Global Pharmaceutical Contract Manufacturing Forecast: Revenue ($bn), 2014, 2020 and 2026
  • Figure 5.3: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.1: The Leading National Vaccine Contract Manufacturing Markets: Market Share (%) by Region, 2015
  • Figure 6.2: The US Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 6.3: The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2015
  • Figure 6.4: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.5: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.6: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.7: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.8: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.9: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.10: The Japanese Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Figure 6.11: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2014-2026
  • Figure 6.12: The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2014-2026
  • Figure 6.13: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.14: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.1: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2014
  • Figure 7.2: Catalent: Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.3: Catalent: Revenue ($m) by Segment, 2011-2015
  • Figure 7.4: Catalent: Marker Shares (%) by Segment, 2015
  • Figure 7.5: Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 7.6: Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2014-2015
  • Figure 7.7: Lonza Custom Manufacturing: Revenue ($m )and AGR (%), 2010-2014
  • Figure 7.8: Meridian Bioscience: Revenue ($m), andAGR (%), 2010-2014
  • Figure 7.9: Meridian Bioscience: Revenue ($m) by Segment, 2011-2014
  • Figure 7.10: Meridian Bioscience: Market Share (%) by Segment,2014
  • Figure 8.1: Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2016-2026
  • Figure 9.1: Vaccine & Vaccine Contract Manufacturing Market: AGR(%), 2015-2026

Companies Listed

  • Aeras Global
  • AfriVax
  • AmProtein
  • Antigenics
  • Artelis
  • AstraZeneca
  • ATM Life Sciences
  • AVEO Pharmaceuticals
  • Balian Hissen Bio-Pharm
  • Baxter BioPharma Solutions
  • Bayer
  • Beijing Tiantan Biological Productions
  • Berna Biotech
  • Bharat Biotech International Limited
  • Binnopharm
  • BioKangtai
  • Boehringer Ingelheim Biopharmaceuticals (China)
  • Cadila Pharmaceuticals
  • Catalent
  • Cellexus Limitied
  • Crucell
  • CSL Biotherapies
  • Daiichi Sankyo
  • GE Healthcare
  • GlaxoSmithKline
  • Hikma
  • Hualan Biological Bacterin
  • Hydone
  • Intercell Corporation
  • Invitrogen
  • Irvine Scientific
  • Kuhner
  • LG Life Sciences
  • Lonza
  • Medicago
  • Meissner Filtration
  • Merck
  • Merck Serono
  • Micron Technologies
  • Millipore
  • Mitsubishi Tanabe Pharma (MTPC)
  • MorphoSys
  • MP Biomedicals
  • Novartis
  • Novavax
  • Organon Teknika Corporation
  • Pall Life Sciences
  • Paragon Bioservices
  • Patheon
  • PBS Biotech
  • Pfenex
  • Pfizer
  • Philip Morris Investments
  • Pierre-Guerin Biolafitte
  • Protein Sciences Corporation
  • Refine Technology
  • Sanofi
  • Sartorius Stedim
  • Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd.
  • Sigma Aldrich
  • Thermo Fisher
  • Vector Solutions
  • Vivalis
  • Wave Biotech
  • Wyeth Pharmaceuticals
  • Xcellerex
  • Xencor

Organisations Mentioned in the Report

  • Biomedical Advanced Research and Development Authority (BARDA)
  • Center for Disease Control (CDC)
  • China Food and Drug Administration (CFDA)
  • Defense Advanced Research Projects Agency (DARPA)
  • Farmaindustria
  • Food and Drug Administration (FDA)
  • Insitut Pasteur
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • U.S Department of Homeland Security
  • U.S. Department of Health and Human Services Office
  • World Health Organisation (WHO)
Back to Top